



Rafael MALDONADO, Full Professor of Pharmacology (*Catedrático de Universidad*)
Laboratory of Neuropharmacology, University Pompeu Fabra (UPF), PRBB.

C/Dr Aiguader 88, 08003 Barcelona, Spain

rafael.maldonado@upf.edu

H-index = 79

387 scientific articles

22407 citations,

Rafael Maldonado, MD, PhD, received his **Medical Degree** in 1985 from the School of Medicine of the University of Cadiz (Spain), where he also obtained a **PhD in Neuropsychopharmacology** in 1988 on the effects of benzodiazepines and antidepressants on morphine dependence. In 1990, he obtained a **PhD in Molecular Pharmacology** (INSERM U 266) at the School of Pharmacy (University René Descartes Paris V, France) on the participation of the endogenous opioid system on the development of opioid dependence. He was a postdoctoral fellow (1990-1991) at The **Scripps** Research Institute (La Jolla, USA), directed by Prof. G.F. Koob, where he studied the neuroanatomical substrate of opioid dependence and cocaine self-administration. Thereafter, he returned to the laboratory of Molecular Pharmacology (INSERM U266), directed by Prof. B.P. Roques in Paris, obtained permanent position as Scientific Researcher (CR-1) in the INSERM (1992) and lead a pharmacological team devoted to the study of the cannabinoid and opioid systems by using pharmacological and molecular approaches. In 2000, he obtained a permanent position as Professor at the **UPF** in Barcelona, where he is director of the Laboratory of Neuropharmacology, and studies the physiological role of the **endogenous cannabinoid and opioid systems** in drug addiction, metabolic, affective and cognitive disorders, pain and eating disorders, with a particular focus in the development of novel **behavioural models** and **novel treatments** for those disorders.

He is/has been the **PI** of **80 projects** funded by **public agencies** and over **70 projects** funded by the **pharmaceutical industry**, has **2 models of utility** (licensed) and **11 patents** (7 licensed/commercialised). He has published **387 peer-reviewed original publications**, more than **60 book chapters** and **5 books**, entitled "Mechanisms of Opiate Withdrawal" (Springer Verlag, 1996), "Cannabis. Quels effets sur le comportement et la santé? Expertise collective" (INSERM, 2001), "Molecular Biology of Drug Addiction" (Humana Press, 2003), "Addictiveness and Attractiveness of Tobacco Additives" (European Commission, 2010) and "Alternative Models in Drug Discovery and Development Part I" (Wiley, 2013).

He won the following awards: Pharmacology **Almirall** (1992), Pharmacology **Uphjon** (1994), **Young Researcher** of the Spanish Society of Pharmacology (1995), the **Research Distinction** of the Generalitat of Catalunya (2000), the **UPSA** prize on Pain Research (2002), the **Excellence Annual Award** of the National Hispanic Science Network (**NHSN**)-National Institute of Drug Abuse (**NIDA**)-USA (2006), **Social Council** of the University Pompeu Fabra to the Transfer of Knowledge and the **ICREA Academy** of the Generalitat de Catalunya (2008, 2015 and 2020), **Antoni Esteve Foundation** (2011 and 2015) and **Grünenthal Foundation** to Pain Research (2013), and "Constantes y Vitales" Award for best biomedical publication (2022).

Rafael Maldonado is a Member of the **National Academy of Pharmacy of France** (2009), of the **Editorial Board** of 9 journals, including *European Journal of Pain*, *European Neuropsychopharmacology*, *Addiction Biology* and *The Scientific World Journal*, and **reviewer** of the main scientific journals, including Nature and Science, and funding agencies, and an expert member of **NIH** and **EC** panels. He is an **expert member** of **NIH** and **EC** panels. He has been an **external advisor** of the **WHO**, and **European Coordinator** of FP7 (NeuroPain) and FP6 (PHECOMP) collaborative projects, three BIOMED programs, and one PECO program of the European Commission, as well as coordinator and principal investigator of a **R01 NIH grant**. He was the coordinator of a Mixed Pre-clinical R+D Unit between the UPF and Laboratorios Esteve for the research and development of new drugs for the treatment of pain (2015-2020). He has been advisor/consultant to several public bodies (e.g. WHO, EMCDDA, European Commission DGs SANCO & RTD, NIH-NIDA, Vatican Academy of Sciences, Spanish and Catalan Parliaments) and to pharmaceutical companies (e.g. SANOFI-AVENTIS, Grünenthal, GW Pharma, Rhodes Pharmaceuticals, Pharmaleads, Aelis Farma, Aptys, Esteve, Ferrer, Almirall, among others), including R+D projects with many of them.